Bristol-Myers Squibb to buy Amylin for $5.3 billion
Bristol-Myers Squibb Co. plans to acquire Amylin Pharmaceuticals Inc. for $31 per share in cash, pursuant to a cash tender offer and second-step merger, for an aggregate purchase price of about $5.3 billion.